Xeris Biopharma Holdings, Inc. (XERS) Stock Analysis
Xeris Biopharma pairs Recorlev’s rapid growth and 86% gross margins with debt reduction and XP-8121 upside, offering attractive five-year potential—but clinical execution and payer access remain decisive.
Overview
Xeris Biopharma is a U.S.-focused commercial-stage specialty biopharmaceutical company selling Recorlev for endogenous Cushing’s syndrome, Gvoke for severe hypoglycemia, and Keveyis for primary periodic paralysis, with additional licensing, research, and royalty revenue from XeriSol and XeriJect. It has transitioned from an early-stage clinical business into a growing commercial platform, with five-year historical revenue CAGR of approximately 36%. **Recorlev is the central growth engine:** Q2 2026 product sales were $56.78 million, up 81.0% year over year, contributing 61.6% of product revenue. Total Q2 revenue rose 28.7% to $92.10 million, gross margin expanded 400 basis points to 86.0%, and Adjusted EBITDA increased 53.2% to $19.30 million. The $31.10 million GAAP net loss was driven substantially by a $30.8 million non-cash charge tied to retirement of convertible notes. Management tightened FY2026 revenue guidance to $385–$390 million, approximately 33% growth at midpoint, and retired the 2028 notes, saving about $3 million in annual interest. Valuation is 4.6x FY2026E sales and 3.7x FY2027E sales at $9.87 per share. **Near-term catalysts are continued Recorlev uptake and XP-8121 Phase 3 initiation by year-end 2026;** the latter targets a 2030 launch and substantial long-term growth.